AKT1 and thyroid gland carcinoma: Similarly, in BRAF inhibition therapy for thyroid cancer, the combination of a BRAF inhibitor (PLX4032) with a c-Met inhibitor (PHA665752) was also able to effectively inhibit the 2 major signaling pathways (MAPK and PI3K/AKT), thereby enhancing the therapeutic response and overcoming the resistance caused by a single inhibitor (98).